Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence

Since the introduction of the Milan criteria in 1996, liver transplantation has become the best treatment option for many patients with early non-resectable hepatocellular carcinoma (HCC), with expected five-year patient survivals in excess of 70% [1]. Despite strict candidate selection, some 10–15% of patients still develop a post-transplant recurrence. While the liver transplant community is endeavouring to lower these figures, refining selection criteria and exploring (neo-)adjuvant cancer treatments, the treatment of the patients with recurrence has received little systematic attention and is still in its infancy, mainly due to the limited number of patients.